16th November 2018 – Global Bevacizumab Biosimilar Market by Application spans Analytical, Pharmacokinetic, Clinical Data, Pharmacology, and Toxicology Data. Currently, there is no acknowledged biosimilar for bevacizumab, a monoclonal antibody used for treating advanced solid tumors,counting metastatic colorectal cancer (mCRC) and advanced or metastaticnon-squamous non-small-cell lung cancer (mNSCLC).
Bevacizumab is a humanized monoclonal antibody. It constrains angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor A (VEGF-A). Bevacizumab can accordingly slow the growth of new blood vessels in tumor’s and is used to treat various cancers, including colorectal, lung, breast, glioblastoma, kidney and ovarian.
Request a Sample Copy of Bevacizumab Biosimilar Market Report @ https://www.millioninsights.com/industry-reports/bevacizumab-biosimilar-market/request-sample
In the United States, it is accepted for giving glioblastoma (GBM) and metastatic ovarian cancer (mOC), and in the European Union (EU) it is indicated for patients with metastatic breast cancer (mBC). Bevacizumab has been exposed to prolong existence in patients with these cancers when combined with chemotherapy in the global Bevacizumab Biosimilar Industry. The measured physicians who did not regularly endorse bevacizumab, those from emerging markets were more probable to cite access as a fence to indorsing across all tumors types. Further, physicians in the United States and EU found it easier to access the drug when treating patients with mCRC, mNSCLC, and mOC than physicians in emerging markets.
U.S. physicians could willingly admit bevacizumab for treatment of GBM than physicians in the other two markets, while EU physicians found it easier to admission the drug for mBC. The major reasons for the apparent barriers to access were that the drug’s costs were “not compensated by healthcare system/private insurance,” and the high out-of-pocket (OOP) costs to the patient. These fences were most commonly cited by physicians in developing markets, although more than high of American defendants said lack of repayment was a barrier to recommending the drug for mOC, associated with 55% of physicians in developing markets and just in the EU.
The major manufacturers covered in this report
• Reliance lifesciences
• Celgene Corporation
• Fujifilm Kyowa Kirin Biologics
• Hetero Drugs
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
• Colorectal Cancer
• Lung Cancer
• Breast Cancer
• Renal Cancer
• Brain Cancer
Access Bevacizumab Biosimilar Market Report with TOC @ https://www.millioninsights.com/industry-reports/bevacizumab-biosimilar-market
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Bevacizumab Biosimilar in these regions, from 2013 to 2025 (forecast), covering
• North America
• Southeast Asia